Jazz Pharmaceuticals Executive and Leadership Team

Bruce Cozadd, the Chairperson and Chief Executive Officer at Jazz Pharmaceuticals, directs the overarching corporate strategy and long-term vision for the global biopharmaceutical enterprise. Overseeing the integration of internal R&D with strategic acquisitions, the Chairperson and Chief Executive Officer ensures the company maintains a competitive edge in neuroscience and oncology markets. This leadership role involves constant collaboration with the Board to align operational goals with patient-centric outcomes across North American and European territories. By fostering a culture of innovation, Bruce Cozadd drives the development of medicines for serious diseases with limited treatment options. The Chairperson and Chief Executive Officer manages the executive team to optimize resource allocation and maximize shareholder value. Through rigorous oversight of the global portfolio, Cozadd secures the company's position as a leader in specialized medicine, ensuring sustainable growth and continued scientific advancement within the complex pharmaceutical landscape.

Taryn Stinson, the Director, Chief of Staff To the Chief Financial Officer at Jazz Pharmaceuticals, manages the financial planning processes and administrative workflows supporting the global fiscal strategy. Overseeing the coordination of financial reporting and capital allocation, the Director, Chief of Staff To the Chief Financial Officer ensures that budgetary resources align with the company's R&D and commercial objectives. This role involves facilitating communication between the finance department and other executive functions to maintain fiscal discipline across international operations. By streamlining the decision-making process for the Chief Financial Officer, Taryn Stinson enhances the efficiency of the entire financial organization. The Director, Chief of Staff To the Chief Financial Officer monitors key performance indicators to support long-term financial stability and growth. Through meticulous oversight of financial projects, Stinson enables the company to invest effectively in the development of medicines for serious diseases, ensuring that fiscal health supports the broader mission of medical innovation.

Jessica Ungerleider, the Commercial Strategy & Planning Chief of Staff at Jazz Pharmaceuticals, coordinates the execution of market-entry initiatives and commercial roadmaps. Managing the alignment between cross-functional teams, the Commercial Strategy & Planning Chief of Staff ensures that product launches for neuroscience and oncology therapies meet rigorous performance benchmarks. This role involves analyzing global market trends to refine the commercial approach across diverse international regions. By streamlining communication between departments, Jessica Ungerleider facilitates the rapid deployment of resources to support patient access programs. The Commercial Strategy & Planning Chief of Staff monitors the efficacy of current commercial models, adjusting tactics to address shifting healthcare demands. Through data-driven insights, Ungerleider optimizes the commercial pipeline, ensuring that the company effectively delivers life-changing treatments to patients. This position remains vital for maintaining operational agility and achieving the ambitious growth targets set for the global biopharmaceutical portfolio.

Kimberly Chaney, the HR Chief of Staff at Jazz Pharmaceuticals, directs the operational efficiency of human resources initiatives and organizational development programs. Overseeing the implementation of talent management strategies, the HR Chief of Staff ensures that the workforce remains aligned with the company's mission to address serious diseases. This role involves coordinating with leadership to foster an inclusive culture that attracts top scientific and commercial talent across global facilities. By managing the internal communication flow within the HR department, Kimberly Chaney optimizes the delivery of employee support services and professional development opportunities. The HR Chief of Staff monitors organizational health metrics to drive engagement and retention in a competitive biopharmaceutical environment. Through strategic planning, Chaney supports the company's growth by ensuring that human capital remains a core strength. This leadership function remains essential for maintaining the operational excellence required to sustain a global presence in the pharmaceutical industry.

Arthur Louie, the Chief Medical Officer at Jazz Pharmaceuticals, directs the clinical development programs and medical affairs strategy for the neuroscience portfolio. Overseeing the design and execution of clinical trials, the Chief Medical Officer ensures that all therapeutic candidates meet the highest standards of safety and efficacy before reaching patients. This role involves collaborating with regulatory bodies and medical experts to advance the company's pipeline in sleep medicine and movement disorders. By providing clinical guidance to the R&D teams, Arthur Louie accelerates the transition of innovative molecules from the laboratory to the clinic. The Chief Medical Officer monitors the medical landscape to identify emerging treatment gaps and opportunities for therapeutic expansion. Through rigorous scientific oversight, Louie ensures that the company's medical strategy remains grounded in evidence-based practice. This position is critical for maintaining the integrity of the clinical portfolio and delivering meaningful health outcomes for patients suffering from complex neurological conditions.

Robert Iannone, the Executive VP, Global Head of Research & Development & Chief Medical Officer at Jazz Pharmaceuticals, directs the entire R&D lifecycle and medical strategy for oncology and hematologic malignancies. Overseeing the discovery and development of novel therapies, the Executive VP, Global Head of Research & Development & Chief Medical Officer ensures that the company's scientific pipeline addresses critical unmet needs in solid tumors. This role involves managing global research teams and licensing partnerships to expand the portfolio of life-saving medicines. By integrating clinical insights with research initiatives, Robert Iannone drives the advancement of complex oncology treatments from early-stage development to regulatory approval. The Executive VP, Global Head of Research & Development & Chief Medical Officer collaborates with the executive team to prioritize high-impact projects that align with the company's long-term growth strategy. Through scientific leadership, Iannone ensures that the company remains at the forefront of medical innovation, delivering transformative solutions to patients worldwide.

Heidi Manna, the Executive VP & Chief People Officer at Jazz Pharmaceuticals, directs the global human resources strategy and organizational culture initiatives. Overseeing the development of talent acquisition, compensation, and employee engagement programs, the Executive VP & Chief People Officer ensures that the company attracts and retains the expertise necessary to drive biopharmaceutical innovation. This role involves aligning the workforce with the company's mission to provide specialized medicines for serious diseases. By implementing scalable HR systems across international offices, Heidi Manna supports the operational needs of a growing global enterprise. The Executive VP & Chief People Officer collaborates with the leadership team to foster a high-performance environment that values diversity and scientific excellence. Through strategic workforce planning, Manna ensures that the company maintains the human capital required to sustain its competitive position. This leadership role remains central to building a resilient organization capable of navigating the complexities of the global pharmaceutical market.